8-K/A: Neuronetics Revises 2024 Financial Results Following Greenbrook Acquisition Accounting Updates

Neuronetics has updated its financial results for Q4 and the full year 2024 due to non-cash revisions related to the Greenbrook TMS Inc. acquisition and shares outstanding.

Summary

• Neuronetics has issued an amendment to its previous report to update financial results for the three months and year ending December 31, 2024.
• The updates are due to non-cash revisions related to the acquisition of Greenbrook TMS Inc. and shares outstanding.
• These revisions impact the fourth quarter and full year 2024 results.
• The updated results include a $0.6 million reduction in the 2024 bonus accrual assumed from Greenbrook, increasing operating expenses.
• The net loss for Q4 2024 increased from $(12.2) million to $(12.7) million, and the net loss per share increased from $(0.33) to $(0.34).
• Adjusted EBITDA for Q4 2024 decreased from $0.1 million to $(0.4) million.
• For the full year 2024, the net loss increased from $(43.2) million to $(43.7) million, and the net loss per share increased from $(1.37) to $(1.38).
• Adjusted EBITDA for the full year 2024 decreased from $(21.3) million to $(21.8) million.
• The company has filed its Annual Report on Form 10-K, which fully reflects these accounting updates.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the revisions leading to worse financial results than initially reported. While the changes are attributed to accounting adjustments, they still reflect a less favorable financial picture.

Negatives

• The net loss for Q4 2024 increased from $(12.2) million to $(12.7) million.
• The net loss per share for Q4 2024 increased from $(0.33) to $(0.34).
• Adjusted EBITDA for Q4 2024 decreased from $0.1 million to $(0.4) million.
• The net loss for the full year 2024 increased from $(43.2) million to $(43.7) million.
• The net loss per share for the full year 2024 increased from $(1.37) to $(1.38).
• Adjusted EBITDA for the full year 2024 decreased from $(21.3) million to $(21.8) million.

Risks

• The company's ability to achieve or sustain profitable operations is uncertain due to its history of losses.
• The company relies on the sale and use of the NeuroStar System to generate revenues.
• The company's ability to retain talent is a risk.
• Availability of coverage and reimbursement from third-party payors for treatments using the company's products is a risk.
• Developments in competing technologies and therapies could negatively impact the company.
• The company's revenue concentration among a small number of customers is a risk.
• The company's ability to achieve cash flow positive in the third quarter of 2025 is uncertain.

Future Outlook

The company's ability to achieve cash flow positive in the third quarter of 2025 is a forward-looking statement subject to risks and uncertainties.

Industry Context

Neuronetics operates in the mental health technology sector, offering non-drug treatments for conditions like depression and OCD. The acquisition of Greenbrook TMS Inc. is part of the company's strategy to expand its treatment center network and offer NeuroStar Therapy more broadly.

Comparison to Industry Standards

• It is difficult to compare Neuronetics directly to industry standards without knowing the specific benchmarks for companies offering similar neuromodulation therapies.
• Companies like MagVenture and Brainsway also offer TMS (Transcranial Magnetic Stimulation) systems, but their financial results and business models may differ.
• Greenbrook TMS Inc., prior to its acquisition, was a direct competitor operating treatment centers, and its performance could be used as a benchmark for Neuronetics' Greenbrook operations.
• Comparing Neuronetics' revenue growth, gross margins, and operating expenses to those of other medical device and mental health service providers would provide a more comprehensive assessment.

Stakeholder Impact

• Shareholders may react negatively to the revised financial results.
• Employees may be concerned about the company's profitability and future prospects.
• Customers may be affected if the company's financial difficulties impact its ability to provide services.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.

Key Dates

Keywords

Neuronetics, financial results, Greenbrook TMS, acquisition, adjusted EBITDA, net loss, NeuroStar, mental health, Form 8-K, Form 10-K